Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Tc Biopharm [Holdings] Plc ADR (TCBP)

Tc Biopharm [Holdings] Plc ADR (TCBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments FinancialNewsMedia - Tue Oct 24, 2023

EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END

TCBP : 0.6600 (+0.15%)
CVM : 0.7299 (-4.60%)
INVO : 0.8330 (-2.91%)
SNY : 47.71 (+0.44%)
PFE : 26.36 (+2.29%)
TC BioPharm Announces Grant Funding in Collaboration with Queen Mary University of London (QMUL) PR Newswire - Tue Sep 5, 2023

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform...

TCBP : 0.6600 (+0.15%)
TC BioPharm to Present at H.C. Wainwright 25th Annual Global Investment Conference PR Newswire - Tue Aug 29, 2023

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...

TCBP : 0.6600 (+0.15%)
TC BioPharm Maintains Nasdaq Listing PR Newswire - Mon Jul 31, 2023

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...

TCBP : 0.6600 (+0.15%)
TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast Newsfile - Thu Jul 6, 2023

Phoenix, Arizona--(Newsfile Corp. - July 6, 2023) - The Stock Day Podcast welcomed TC BioPharm Holdings, PLC. (NASDAQ: TCBP) ("the Company"), a clinical-stage biopharmaceutical company focused on the discovery,...

TCBP : 0.6600 (+0.15%)
TC BioPharm Increases Allogeneic Car and Partnering Focus for Advancement of TCB-008 PR Newswire - Wed Apr 26, 2023

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company today laid out a fundamental...

TCBP : 0.6600 (+0.15%)
TC BioPharm Announces Closing of $5.5 Million Public Offering PR Newswire - Thu Mar 30, 2023

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...

TCBP : 0.6600 (+0.15%)
TC BioPharm Announces Pricing of $5.5 Million Public Offering PR Newswire - Tue Mar 28, 2023

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...

TCBP : 0.6600 (+0.15%)
TC Biopharm Announces Corporate Restructuring, Reduction in Overhead PR Newswire - Wed Mar 22, 2023

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...

TCBP : 0.6600 (+0.15%)
TC BioPharm Receives Extension from Nasdaq Hearings Panel to Regain Compliance With Listing Rule 5550(b)(2) PR Newswire - Thu Mar 16, 2023

/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...

TCBP : 0.6600 (+0.15%)

Barchart Exclusives

Oracle Stock Is Off Its Highs and Could Be Cheap Here Barchart - 34 minutes ago
Oracle Corp. produced higher revenue in Q2 but lower free cash flow and FCF margins. However, ORCL stock is now off its highs and could be undervalued here. Shorting out-of-the-money puts is one way to play it. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot